https://eureka.patsnap.com/resources/blog/rd-blog/endotoxin-and-bioburden-control-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Endotoxin & Bioburden Control
Endotoxin and bioburden control patents: leaders, filing trends and open claim space
  • 18 filings in 2018 remains the peak year so far, with the field not yet back above that level through 2024, the last complete filing year in this dataset.
  • One assignee holds 39 records against a fifth-place count of 14, a steep drop-off that points to a single entity setting the pace across a 24-company ranking.
  • G01N material analysis and testing covers 52.8% of the 142 records, while control-systems and digital-transmission classes each sit under 13%, marking where claim density is thin.
Get a prior-art report on your approach
142
Published Records
0%
Filing Growth 2021→2024
US
Leading Jurisdiction
24
Active Filers Ranked

Filing growth compares 2021 (1 records) with 2024 (1) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field.

Published byPatsnap Research··6 min readSourced from Patsnap Eureka
Field Overview

What this landscape covers

Endotoxin and bioburden control sits at the intersection of pharmaceutical quality control, analytical chemistry and, increasingly, digital manufacturing execution. The search underlying this page combines detection and depyrogenation terms — recombinant factor C, action limit, recovery study — with the operational language of water systems, sampling plans and hold-time limits, capturing both the assay science and the manufacturing controls built around it.

142 published records across 2015 to mid-2026 form the base of this analysis, spanning material-testing methods, cosmetics and medicinal-preparation uses, and a smaller but distinct cluster of control-system and connectivity filings tied to manufacturing execution.

Filing activity and technology mix, 2017–2026
  1. 1BIOMERIEUX DEUT GMBH39
  2. 2HYGLOS INVEST GMBH36
  3. 3SMP LOGIC SYST21
  4. 4AOBIOME LLC16
  5. 5CENT DE INVESTIGACION & DESARROLLO DE MEDICAMENTOS CIDEM14
  6. 6UNIVERSITY OF HAVANA13
  7. 7NANOMIX INC3
  8. 8ALEXION PHARMACEUTICALS INC2
  9. 9HAWAII CHITOPURE2
  10. 10CHAMPION MILTON KEITH2
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Endotoxin and Bioburden Control covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Let an AI agent run this analysis on your own technology

Pick a task. Every answer cites the patents behind it.

10,000 free credits to start
The Data

Filing trend and technology composition

Two views of the same 142-record set: how filing activity has moved year over year, and how those records break down across IPC subclasses.

Filing activity since 2017

Annual filings ran from 3 in 2017 to a peak of 18 in 2018, and by the 2021–2024 window growth was flat at 0% (1 filing in 2021, 1 in 2024). 2025 and 2026 counts are still incomplete because publication typically lags filing by around 18 months, so the visible tail should not be read as a slowdown.

Filing activity since 20170510152032017182018201920202021202220232024202502026Most recent year is partial — publication lag means later filings are not yet visible.

Technology composition by IPC subclass

G01N (material analysis and testing) accounts for 52.8% of the 142 records, well ahead of G05B control systems (12.7%), A61K medicinal preparations (11.3%) and A61Q cosmetics use (10.6%). C12Q enzyme/DNA-based testing, H04L digital transmission, G06F data processing and H04W wireless networks each sit at 9.9% or below, marking the smaller, more specialised branches of the field.

Technology composition by IPC subclassG01N · Material analysis & testing7552.8%G05B · Control & regulating systems1812.7%A61K · Medicinal preparations1611.3%A61Q · Cosmetics use1510.6%C12Q · Measuring & testing involving …149.9%H04L · Digital information transmissi…107.0%G06F · Electric digital data processi…64.2%H04W · Wireless communication networks64.2%Other1611.3%

Shares are the percentage of the 142 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Endotoxin and Bioburden Control covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Endotoxin and Bioburden Control with Eureka

This page is one run against one query. Ask Eureka your own question about endotoxin and bioburden control and every answer comes back with the patent numbers behind it.

Try Eureka
Key Patents

Most-cited records in this landscape

Representative Filing
US20170227529A12017-08-10

US20170227529A1 — Unmasking endotoxins in solution

BIOMÉRIEUX DEUTSCHLAND GMBH

The invention relates to unmasking endotoxins in compositions so that previously present, but undetectable endotoxins are rendered detectable.Filed by Biomérieux Deutschland, published 2017-08-10.

US20170227529A1 — patent drawing 1US20170227529A1 — patent drawing 2
View full record
Highest-citation records
#Publication no.Patent titleCitations
1WO2008063503A2Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin …58
2US20080248508A1Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin …58
3US20200133224A1Cloud-Controlled Manufacturing Execution System (CLO-cMES) for use in pharmaceutical manufacturing process co…30
4WO2011146463A2Enhancing endotoxin detection29
5US20150060272A1Amperometric detection of limulus amebocyte lysate activation by endotoxin and/or 1-3-beta-d-glucan27
6WO2017004534A2Microbiome-compatible cosmetics18
7US20080221722A1Methods of interfacing nanomaterials for the monitoring and execution of pharmaceutical manufacturing process…15
8US20080294361A1Intelligent execution system for the monitoring and execution of vaccine manufacturing10
9US20180369129A1Microbiome-compatible cosmetics9
10US20100217425A1Manufacturing execution system (MES) and methods of monitoring glycol manufacturing processes utilizing funct…7

Citation counts reflect influence within the searched corpus and skew toward older records; they are not a measure of current commercial importance.

Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Endotoxin and Bioburden Control covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the numbers mean for strategy

Three patterns stand out once the filing trend, technology mix and citation data are read together.

Concentration at the top
39 vs 14
leader vs fifth place

One assignee sets the pace

The leading assignee holds 39 records against 14 at fifth place in a 24-company ranking, a gap wide enough that competitive tracking should treat this filer as the benchmark rather than one of several peers.

Assignee ranking, 24 companies
Flat recent growth
0%
2021 to 2024 filings

Activity plateaued, not accelerated

Filings held at 1 in both 2021 and 2024, a 0% change across that span. Combined with 2025-2026 data still filling in, the field reads as steady rather than expanding.

Filing growth, 2021-2024
Testing dominates
52.8%
of 142 records in G01N

Material analysis is the crowded core

Over half of all records touch G01N material analysis and testing, meaning new filers face the densest prior art there. Control systems, cosmetics and enzyme-based testing each occupy a tenth or less of the record base.

IPC composition, 142 records
Old citations lead
58 citations
top-cited record

Influence sits with early chitosan work

The two most-cited records both concern ultra-low-endotoxin chitosan products, each cited 58 times. Their age within the corpus means high citation counts mark historical influence on the field's assay science, not current filing direction.

Most-cited records table
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to endotoxin and bioburden control, with the prior art for and against each one.

Find the white space →
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Endotoxin and Bioburden Control covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players & White Space

Who is active, and where the gaps sit

The assignee ranking is dominated by one filer with a long tail behind it; the technology mix points to specific branches that remain lightly claimed.

Leader
39 records
top-ranked assignee

A single filer ahead of the field

The top assignee's 39 records outpace the rest of the 24-company ranking by a wide margin, with fifth place at 14 and tenth place at just 2, indicating a long tail of smaller and single-filing entrants.

24 companies ranked
Co-filing cluster
10 pairs
co-assignee relationships

A tight research collaboration

The strongest co-assignee pairs link a drug-development centre with marine-research and university partners, suggesting institutional research collaboration rather than broad industry cross-licensing.

Co-assignee pairs, strongest at 8 shared records
Recent momentum
0 in latest year
across tracked assignees

Momentum has cooled across the board

Every assignee tracked for recent-year momentum, including the ranking leader, shows zero filings in the latest year, consistent with the general publication lag rather than a genuine stop in R&D.

Recent-year momentum by assignee
🔍
Under-claimed branches worth a closer look
These sub-areas sit behind the dominant G01N testing cluster and carry comparatively few filings.
Wireless-linked bioburden sensors (H04W)Cloud-based batch release controlDigital hold-time-limit tracking (H04L)Enzyme-based rapid endotoxin assays (C12Q)Cosmetics-grade bioburden thresholds (A61Q)
Rank all filers by momentum →
Recent-year filing momentum by assignee
AssigneeRecent yearYoY
Hyglos Invest GmbH0—
SMP LOGIC SYST0-100%
AOBiome LLC0—
BIOMERIEUX DEUT GMBH0—
Center for Drug Research and Development (CIDEM)0—
CENT DE INVESTIGACIONES MARINAS0—
University of Havana0—
VEGA HURTADO YAMILE0—
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Endotoxin and Bioburden Control covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next

Where to take this analysis

The dataset points to a concentrated leader, a flat-but-steady filing trend, and specific under-claimed branches. The next step is turning that into a filing or freedom-to-operate decision.

Map claim scope against the leader's portfolio

With one assignee holding 39 of the ranked records, any new filing in material-analysis-based endotoxin detection should be checked against that portfolio's claim scope before drafting.

Explore assignee portfolios in Eureka

Test white-space branches for freedom to operate

Wireless-linked sensing, cloud-based release control and enzyme-based rapid assays each carry comparatively few filings; a targeted search can confirm whether a first claim is realistic there.

Run a white-space search in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Endotoxin and Bioburden Control covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Common questions on endotoxin and bioburden control patents

Answers are grounded in the same dataset. Derived from a Patsnap search on Endotoxin and Bioburden Control covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Endotoxin and Bioburden Control in depth with Eureka

Go past this page: query the whole endotoxin and bioburden control corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.